Eli Lilly and Insitro Collaborate on AI-Driven Therapies for Metabolic Diseases

Eli Lilly, Insitro, AI, Metabolic Diseases, Drug Development, Strategic Agreements, siRNA Therapies, Antibody Therapy, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

BIOSECURE Act: Navigating Industry Implications and Future Directions

BIOSECURE Act, Biotechnology industry, Supply chain disruptions, Chinese pharmaceutical imports, U.S. manufacturing capabilities, Contract development and manufacturing organizations (CDMOs), Pharmaceutical supply chain resilience